Trials / Completed
CompletedNCT06527144
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3mg TQC3721 Suspension for Inhalation | TQC3721 suspension for inhalation is target inhibitor. |
| DRUG | 6mg TQC3721 Suspension for Inhalation | TQC3721 suspension for inhalation is target inhibitor. |
| DRUG | Placebo TQC3721 suspension for inhalation | Placebo without active drug substance. |
Timeline
- Start date
- 2024-09-14
- Primary completion
- 2025-01-16
- Completion
- 2025-03-06
- First posted
- 2024-07-30
- Last updated
- 2025-04-11
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06527144. Inclusion in this directory is not an endorsement.